

Cite this: *Chem. Sci.*, 2021, 12, 14758

All publication charges for this article have been paid for by the Royal Society of Chemistry

Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides†

Jürgen M. Kolos,[†] Sebastian Pomplun,[‡] Sascha Jung,^c Benedikt Rieß,[¶] Patrick L. Purder,^a Andreas M. Voll,^{id} Stephanie Merz,^a Monika Gnatzy,^a Thomas M. Geiger,^a Ingrid Quist-Løkken,^{def} Jerome Jatzlau,^g Petra Knaus,^g Toril Holien,^{id} Andreas Bracher,^h Christian Meyners,^a Paul Czodrowski,^c Vera Krewald,^{id} and Felix Hausch^{id}*^a

Methyl groups can have profound effects in drug discovery but the underlying mechanisms are diverse and incompletely understood. Here we report the stereospecific effect of a single, solvent-exposed methyl group in bicyclic [4.3.1] aza-amides, robustly leading to a 2 to 10-fold increase in binding affinity for FK506-binding proteins (FKBPs). This resulted in the most potent and efficient FKBP ligands known to date. By a combination of co-crystal structures, isothermal titration calorimetry (ITC), density-functional theory (DFT), and 3D reference interaction site model (3D-RISM) calculations we elucidated the origin of the observed affinity boost, which was purely entropically driven and relied on the displacement of a water molecule at the protein–ligand–bulk solvent interface. The best compounds potently occupied FKBPs in cells and enhanced bone morphogenic protein (BMP) signaling. Our results show how subtle manipulation of the solvent network can be used to design atom-efficient ligands for difficult, solvent-exposed binding pockets.

Received 22nd August 2021
Accepted 22nd October 2021

DOI: 10.1039/d1sc04638a

rsc.li/chemical-science

Introduction

Replacement of a hydrogen by a methyl group is the smallest chemical modification in drug design. Although minimal in size, this perturbation can have profound effects on drug-like properties.^{1–4} In favorable cases, the addition of a methyl

group can enhance affinity to the target protein ten-fold and in extreme cases – also known as magic methyl effect – by a factor >100.^{2,3} The possibilities to utilize strategically positioned methyl groups have recently been substantially expanded by the development of sophisticated late-stage methylation reactions.^{4,5} Mechanistically, the methyl-induced affinity gain can be achieved by filling a complementary small hydrophobic pocket (Fig. 1A) or by stabilizing an otherwise unfavorable active conformation (Fig. 1B). Unfortunately, these options are not always available in drug design projects, especially for shallow, solvent-exposed binding pockets as exemplified for FK506-binding proteins (FKBPs). FKBPs belong to the immunophilin family, possess *cis-trans* peptidyl-prolyl isomerase (PPIase) activity and are potential drug targets for several human diseases.^{6,7}

FKBP12 represses BMP-signaling⁸ and drug-like FKBP12 inhibitors are potential treatments for pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, wound healing,⁹ and acute kidney injury.¹⁰ Moreover, FKBP51 has emerged as a promising target for depression, obesity, and chronic pain.^{6,11–14} Microbial or parasitic FKBPs (sometimes also called Macrophage infectivity potentiators, Mips) are important for replication of the pathogens and FKBP/Mip inhibitors in turn have anti-infective potential.¹⁵ Finally, FKBPs are the key enabling adaptors for the clinically approved immunosuppressants FK506 and rapamycin as well as for several recently

^aDepartment of Chemistry, Technical University of Darmstadt, Alarich-Weiss-Straße 4, 64293 Darmstadt, Germany. E-mail: felix.hausch@tu-darmstadt.de

^bMax Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804 München, Germany

^cTechnische Universität Dortmund, Fakultät für Chemie und Chemische Biologie, Otto-Hahn-Straße 6, 44227 Dortmund, Germany

^dDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway

^eDepartment of Immunology and Transfusion Medicine, St. Olav's University Hospital, 7030 Trondheim, Norway

^fDepartment of Hematology, St. Olav's University Hospital, 7030 Trondheim, Norway

^gInstitute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany

^hResearch Department Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Planegg, Germany

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1sc04638a

‡ These authors contributed equally.

§ Sebastian Pomplun: Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.

¶ Benedikt Rieß: Department of Chemistry, Technical University of Munich, Lichtenbergstraße 4, 85748 Garching, Germany




Fig. 1 Different roles for methyl groups in ligand–protein interactions and in rational drug design. (A) Established affinity enhancements by hydrogen/methyl replacements. (B) The bicyclic [4.3.1] aza-amide scaffold allows the precise positioning of a methyl group in the binding site of FK506-binding proteins to displace an unfavorable, solvent-exposed water molecule.

identified molecular glues.^{16–22} Previously, we developed bicyclic [4.3.1] sulfonamides,^{23–27} which mimic the core of the natural products FK506 and rapamycin, retain the anti-infective²³ and BMP-stimulating properties^{6,10} of these natural products, but lack their immunosuppressive properties. However, the shallow FKBP binding site generally makes the development of ligands with drug-like properties challenging.^{7,15,28} Here, we exploit the defined rigid architecture of the bicyclic scaffold to strategically install a solvent exposed chiral methyl group that displaces a conserved water molecule, robustly leading to a boost in binding affinity to FK506-binding proteins (FKBPs).

Results

We started our ligand optimization with the [4.3.1] bicyclic scaffold, which efficiently locked the active conformation necessary for binding.^{23–26} The remaining protein surface as well as appending moieties on the ligands are all highly solvent-exposed, without any promising features such as nearby hydrophobic cavities.²⁷ However, upon analysis of nine high resolution co-crystal structures of FKBP51 with bicyclic ligands we identified several reoccurring water molecules (Fig. S1†), including a water close to the R¹ or R² substituent that was conserved in all or most available co-crystal structures (Fig. 2A




Fig. 2 Overview of bicycles in the binding pocket of FKBP51. (A) Superposition of nine cocystal structures of bicyclic [4.3.1] aza-amide ligands (green spheres) in complex with FKBP51 (gray surface from PDB-ID 5OBK). The position of the conserved water molecule is highlighted in blue. (B) Cocystal structures of **1** (PDB-ID: 7APT) in complex with FKBP51, with the conserved water molecule highlighted as blue spheres. The water site predicted via 3D-RISM calculations is superimposed as red sphere. (C) Chemical structure of the representative bicyclic [4.3.1] aza-amide **1**. The C- α -position is highlighted by a pink circle.

and S2†). A computational assessment by 3D-RISM calculations confirmed these water sites (distance to crystallographic water ~ 1 Å, Fig. 3B and S4–S7†). A water in proximity of the R² substituent was found to be energetically favorable ($\Delta G_{\text{local}} = -11.79$ kJ mol⁻¹, Table S1, Fig. S2 & S7†) and therefore not considered for displacement. In contrast, the water close to the R¹ substituent was predicted to be energetically highly unfavorable (local free energy $\Delta G_{\text{local}} = +28.18$ kJ mol⁻¹ for **1**, +26.03 kJ mol⁻¹ for **22**). The predicated interaction energy between this water site and the receptor ($\Delta G_{\text{interact}} = +2.77$ kJ mol⁻¹ for **1**, +3.22 kJ mol⁻¹ for **22**) was considerably low, suggesting a stabilization of the ligand–FKBP complex upon displacement of this water molecule. The strongly preserved occupancy of an energetically unfavorable water site, which is highly solvent-exposed and has only minimal contact




Fig. 3 The (S)- α Me displaces a conserved water molecule from the protein surface. Cocystal structures of **1**^{(S)-Me} (A, PDB-ID: 7APS) and **22**^{(S)-Me} (B, 7APW), each shown as dark green sticks, in complex with FKBP51 (grey surface). The water molecules are indicated as blue spheres, with the conserved water close to the α -position highlighted in red. The binding modes of the corresponding parent compounds **1** (from 7APT) and **22** (from 7APQ) derived from the superimposed structures are shown as light green sticks. Nitrogens, oxygens, sulfur, and chlorines are depicted in blue, red, yellow and green, respectively. The key methyl in the α -position of **1**^{(S)-Me} and **22**^{(S)-Me} is highlighted in magenta.



with the protein, is highly unusual.^{29,30} We thus set out to explore the role of this water molecule in more detail.

To explore possible extension vectors of the bicyclic [4.3.1] aza-amide motif, we focused on the C- α position of the R¹ substituent (highlighted in pink in Fig. 2B & C), which is in proximity to the conserved unfavorable water site. We decided to start with an additional methyl as the smallest perturbation. Based on our structural analysis, an (*S*)-methyl group would most likely displace the water molecule of interest. The synthesis of *R*- and *S*- α -methyl analogs of the known

compounds **1** (R¹ = CH₂COOH, Fig. 2) and **2** (R¹ = C₂H₄OH, Fig. S11†)²⁷ commenced with the readily available amino acid derivatives (*R*)- or (*S*)-2-amino-1-propanol **3**, which were sequentially benzyl- and nosyl-protected (Scheme 1). Allylation followed by metathesis with Grubbs 1st generation catalyst gave (*R*)-**5** and (*S*)-**5**, which were nosyl-deprotected, coupled with (*S*)-6-oxo-2-piperidinecarboxylic acid and Boc-protected to furnish amides (*R*)-**6**/*(S)*-**6**. Reduction with DIBAL-H and treatment with HF-pyridine gave the bicyclic [4.3.1] aza-amide intermediates **7**^{(*R*)-Me}/**7**^{(*S*)-Me}. Reaction with the respective sulfonyl chlorides



Scheme 1 Reagent and conditions: (a) NaH, Bn-Cl, THF, reflux, 3 h; (b) Ns-Cl, DIPEA, DCM, 1 h, (*R*)-**4**: 62%, (*S*)-**4**: 66% (over 2 steps); (c) allyl bromide, K₂CO₃, DMF, 2 h; (d) allyltrimethylsilane, Grubbs II, *p*-benzoquinone, DCM, reflux, 6 h, (*R*)-**5**: 53%, (*S*)-**5**: 32% (over 2 steps); (e) thio-phenol, K₂CO₃, DMF, rt, 16 h; (f) (*S*)-6-oxopiperidine-2-carboxylic acid, HATU, rt, DMF, 2 h; (g) Boc₂O, DIPEA, DMAP, DCM, 48 h, (*R*)-**6**: 61%, (*S*)-**6**: 48% (over 3 steps); (h) DIBAL, THF, −78 °C, 15 min; (i) HF-pyridine, DCM, −78 °C, 1 h, **7**^{(*R*)-Me}: 69%, **7**^{(*S*)-Me}: 63% (over 2 steps); (j) benzo[d]thiazole-6-sulfonyl chloride, DIPEA, DMAP, DCM, rt, 16 h, **8**^{(*R*)-Me}: 42%, **8**^{(*S*)-Me}: 33%; (k) BCl₃·SMe₂, DCM, rt, 16 h, **9**^{(*R*)-Me}: 70%, **9**^{(*S*)-Me}: 58%, **11**^{(*R*)-Me}: 76%, **11**^{(*S*)-Me}: 47%; (l) 3,5-dichlorobenzene-1-sulfonyl chloride, DIPEA, DMAP, DCM, rt, 16 h, **10**^{(*R*)-Me}: 46%, **10**^{(*S*)-Me}: 47%; (m) Jones-reagent, acetone, rt, 5 h, **1**^{(*R*)-Me}: 35%, **1**^{(*S*)-Me}: 56%.

Table 1 FP-Assay data of selected compounds

No.	FKBP 12 [nM]	FKBP 51 [nM]	R ¹	R ²	R ³
FK506	0.55 ± 0.08	405 ± 81			
1 ^{(<i>R</i>)-Me}	48	123	CH((<i>R</i>)-CH ₃)COOH	DCB ^a	Vinyl
1	33	172	CH ₂ COOH		
1 ^{(<i>S</i>)-Me}	13	22	CH((<i>S</i>)-CH ₃)COOH		
9 ^{(<i>R</i>)-Me}	>5000	>5000	CH((<i>R</i>)-CH ₃)CH ₂ OH	BTZ ^b	Vinyl
9 ^{(<i>S</i>)-Me}	21	110	CH((<i>S</i>)-CH ₃)CH ₂ OH		
11 ^{(<i>R</i>)-Me}	>5000	>5000	CH((<i>R</i>)-CH ₃)CH ₂ OH	DCB ^a	Vinyl
11 ^{(<i>S</i>)-Me}	3.5	107	CH((<i>S</i>)-CH ₃)CH ₂ OH		
17 ^{(<i>R</i>)-Me}	240	4546	CH((<i>R</i>)-CH ₃)Py	BTZ ^b	Vinyl
17	7.5	294	CH ₂ Py		
17 ^{(<i>S</i>)-Me}	2.2	33	CH((<i>S</i>)-CH ₃)Py		
18	0.52	33	CH ₂ Py	DCB ^a	CH ₂ -OH
18 ^{(<i>S</i>)-Me}	0.29	2.6	CH((<i>S</i>)-CH ₃)Py		
19	0.65	12	CH ₂ Py	DCB ^a	CH ₂ -OMe
19 ^{(<i>S</i>)-Me}	0.33	2.9	CH((<i>S</i>)-CH ₃)Py		
20	6.5	410	CH ₂ Py	BTZ ^b	Ethyl
20 ^{(<i>S</i>)-Me}	1.9	27	CH((<i>S</i>)-CH ₃)Py		
21	5.5	283	CH ₂ Py	BTZ ^b	CH ₂ -OH
21 ^{(<i>S</i>)-Me}	1.5	27.2	CH((<i>S</i>)-CH ₃)Py		
22 ^{(<i>R</i>)-Me}	52	696	CH((<i>R</i>)-CH ₃)Py	BTZ ^b	CH ₂ -OMe
22	2.5	104	CH ₂ Py		
22 ^{(<i>S</i>)-Me}	2.2	32	CH((<i>S</i>)-CH ₃)Py		

^a DCB = 3,5-dichlorobenzene. ^b BTZ = 6-benzothiazole. Values for FKBP52 are similar to FKBP51 and shown in Table S3. **22**^{(*R*)-Me} and **22**^{(*S*)-Me} were synthesized *via* a different route (Scheme S1).



gave sulfonamides **8**^{(R)-Me}/**8**^{(S)-Me} and **10**^{(R)-Me}/**10**^{(S)-Me}, which after treatment with boron trichloride yielded alcohols **9**^{(R)-Me}/**9**^{(S)-Me} and **11**^{(R)-Me}/**11**^{(S)-Me}, respectively. The latter two were further oxidized by Jones oxidation to furnish carboxylic acids **1**^{(R)-Me}/**1**^{(S)-Me}. When testing the binding affinity of the resulting bicycles to FKBP12, 12.6, 51 and 52 *via* a competitive FP-assay (Table S3†), we were delighted to see that the introduction of a methyl group in *S*-configuration (**1**^{(S)-Me}) enhanced affinity for FKBP12 and especially for FKBP51 compared to **1** (Table 1). A similar trend was also observed for the alcohols **2** and **11**^{(S)-Me}. Here, the *R*-configured methyl group in **11**^{(R)-Me} dramatically compromised affinity, similar to the alcohols **9**^{(R)-Me}/**9**^{(S)-Me}.

Hydrazinolysis of **12** (ref. 27) and reductive amination afforded the secondary amines **13a** and a racemic mixture of **13b/c**, which was coupled to commercially available (*S*)-6-oxo-2-piperidinecarboxylic acid followed by Boc-protection (Scheme 2). Reduction with DIBAL-H followed by HF-mediated *N*-acyliminium cyclization yielded the bicyclic [4.3.1] aza-amide building blocks **15** in good overall yields of 10–19% in 8 steps. At this stage, it was possible to separate the two diastereomers **15**^{(R)-Me} and **15**^{(S)-Me} by column chromatography. Reaction with the respective sulfonyl chlorides gave the sulfonamides **16/16**^{(R)-Me}/**16**^{(S)-Me} and **17/17**^{(R)-Me}/**17**^{(S)-Me} ready for testing. Lemieux–Johnson oxidation followed by reduction with sodium borohydride furnished alcohols **18/18**^{(S)-Me} and **21/21**^{(S)-Me}. The former three were methylated with methyl iodide yielding methyl ethers **19/19**^{(S)-Me} and **22**. Reduction of the vinyl group with palladium-catalyzed hydrogenation gave compounds **20/20**^{(S)-Me}.

The obtained α -methylated sulfonamides as well as the respective parent analogs were tested for binding to three human FKBP (FKBP12, FKBP51, FKBP52) by a fluorescence polarization assay (Tables 1 and S3†). We found that binding affinities were consistently stronger for the (*S*)-Me diastereomers compared to the parent analogs ($R^1 = \text{CH}_2\text{R}$). Conversely, the (*R*)-Me diastereomers displayed reduced affinities in most cases, compared to the (*S*)-Me and to the unsubstituted parent

compounds. This trend was consistent for all tested FKBP. Compounds **18**^{(S)-Me} and **19**^{(S)-Me} are picomolar FKBP12 ligands and low nanomolar ligands for FKBP51 and FKBP52 (up to 50-fold better than the prototypical ligand FK506), representing the most potent and ligand-efficient FKBP ligands known to date. They will be provided to the scientific community as donated chemical probes *via* the Structural Genomics Consortium at the Goethe University Frankfurt (SGC Frankfurt) to enable researchers to pharmacologically probe the role of FKBP in well-defined manner (<https://www.sgc-ffm.uni-frankfurt.de/>).

In order to explore the structural basis for the enhanced binding affinity induced by the (*S*)-Me group, we co-crystallized the (*S*)-diastereomers **1**^{(S)-Me} and **22**^{(S)-Me} as well as the respective parent compounds **1** and **22** with the FK1 domain of FKBP51 (Fig. 3). All crystal structures had atomic resolution (**1**: 1.09 Å, **22**^{(S)-Me}: 0.89 Å) allowing a detailed analysis of the binding mode and solvation shell. A superposition revealed only minimal differences between the (*S*)-diastereomers and the parent compounds, with a slight rearrangement of the R^1 group as the only apparent difference. Both conformations enable a hydrogen bond between the pyridine nitrogen or the carboxy group to Tyr113, which is 0.1 Å shorter for the high-affinity (*S*)-Me analogs compared to the non- α -Me derivatives. As expected, the key additional methyl group is largely solvent-exposed and makes only a single van-der-Waals interaction (3.2 Å) with the backbone carbonyl of Gln85. Most importantly, the *S*-methyl indeed displaces the conserved water molecule observed before. This was confirmed by 3D-RISM calculations, which also indicated that no new unfavorable water site appeared (Fig. S2 & S5†). Since methyl groups can profoundly affect binding energies by conformational effects, we investigated the influence of the α -methyl group on intrinsic conformational preferences. The rotational barriers for the NCCN and CNNC bonds were calculated by DFT, using compounds **22**, **22**^{(S)-Me} and **22**^{(R)-Me} as a model system (Fig. 4).



Scheme 2 Reagent and conditions: (a) hydrazine, MeOH, 70 °C, 24 h; (b) **13a**: pyridine-2-carbaldehyde, NaBH₄, EtOH, rt, 4 h, 76% (over 2 steps), **13b/c**: 1 (pyridin-2-yl)ethan-1-one, TTIP, NaBH₄, EtOH, rt, 4 h, 62% (over 2 steps); (c) (*S*)-6-oxopiperidine-2-carboxylic acid, HATU, rt, DMF, 2 h; (d) Boc₂O, DIPEA, DMAP, DCM, 48 h, **14a**: 60%, **14b/c**: 50% (all yields over 2 steps); (e) DIBAL-H, THF, −78 °C, 15 min; (f) HF-pyridine, DCM, −78 °C, 1 h, **15**: 39%, separation of diastereomers: **15**^{(R)-Me}: 39%, **15**^{(S)-Me}: 34% (all yields over 2 steps); (g) 3,5-dichlorobenzene-1-sulfonyl chloride, DIPEA, MeCN, rt, 24 h, **16**: 66%, **16**^{(R)-Me}: 42%, **16**^{(S)-Me}: 42%; (h) benzo[d]thiazole-6-sulfonyl chloride, DIPEA, MeCN, rt, 24 h, **17**: 29%, **17**^{(R)-Me}: 43%, **17**^{(S)-Me}: 43%; (i) OsO₄, NaIO₄, 2,6-lutidine, dioxane/H₂O, rt, 20 h; (j) NaBH₄, EtOH, 1 h, **18**: 47%, **18**^{(S)-Me}: 58%, **21**: 27%, **21**^{(S)-Me}: 70% (all yields over 2 steps); (k) MeI, NaH, rt, 1 h, **19**: 89%, **19**^{(S)-Me}: 92%, **22**: 89%; (l) H₂, Pd/C, 1 h, **20**: quant., **20**^{(S)-Me}: quant.




Fig. 4 Conformational preorganization explains the affinity loss for the (*R*)- α -Me analogs. DFT evaluation of conformations of the CNCC and NCCN dihedral angles next to the α -Me carbon for compounds 22, 22(*S*)-Me and 22(*R*)-Me [grid of 18×18]. Energy maps are colored according to energy (blue: low energy; red: high energy; energies in kcal mol^{-1}). The black asterisk indicates the conformation found in the respective crystal structure (for 22(*R*)-Me: adopted from 22), a black triangle indicates the nearest local minimum, a black square indicates the global minimum.

Two areas of low energy were identified for the CNCC dihedral angle (approx. -100° and 100° , corresponding to the pyridyl group pointing towards or away from Tyr113 when bound to FKBP). These two orientations are strongly preferred by the *S*- α -Me and *R*- α -Me group, respectively. The pyridyl ring itself can rotate more freely, with slight preferences for the NCCN dihedral angle at $\approx 70^\circ$ and -112° , corresponding to the pyridyl nitrogen point to and away from the Tyr113- ϵ -OH. In the co-crystal structures, 22 and 22(*S*)-Me adopt conformations close to

the local minima around $\text{CNCC} \approx 100^\circ$ and $\text{NCCN} \approx 70^\circ$ respectively.

To refine the energy landscape, thermodynamic corrections were computed for selected minima and for the conformations observed in the crystal structure (Table S6†). For 22 and 22(*S*)-Me, the crystal structure conformations were found to be iso-energetic to their respective local minimum ($\Delta\Delta G = 0.2 \text{ kcal mol}^{-1}$) and slightly disfavored compared to the global minimum ($\Delta\Delta G = 2.8\text{--}2.9 \text{ kcal mol}^{-1}$). While the energetic penalties between the global minima and the active conformations are similar for 22 and 22(*S*)-Me, the energy landscape of 22 indicates a higher degree of conformational freedom with two approximately equally accessible valleys at CNCC dihedral angles around -110° and $+90^\circ$ approximately equally accessible. This effect may account for a difference in binding affinity of at most a factor of two. Therefore, conformational preorganization cannot fully explain the enhanced affinity of (*S*)-Me-compounds over their respective non-methylated analogs. For 22(*R*)-Me, however, the predicted key hydrogen bond-enabling conformation is $\Delta\Delta G = 5.7 \text{ kcal mol}^{-1}$ less favorable compared to the global minimum, explaining the reduced affinities of the *R*-isomers.

To explore the thermodynamic signature for the enhanced affinity of α -methyl-containing bicyclic [4.3.1] aza amides we used isothermal titration calorimetry (ITC)^{13,31} (Table S4†). The affinities measured with ITC were fully consistent with the FP-assay data (Fig. S13†). Overall, the bicyclic [4.3.1] aza-amide FKBP ligands were highly enthalpy-driven, as observed before.^{12,23} Strikingly, the comparison of the (*S*)- α -Me derivatives with their non-methylated analogs revealed that the affinity gain imparted by the additional methyl group was based exclusively on a gain in entropy (Fig. 5 & S14†), without any entropy-enthalpy compensation. This is consistent with enhanced degrees of freedom for the solvent shell of the (*S*)- α -Me derivatives-FKBP51 complexes compared to their non-methylated counterparts.

Finally, we tested if the high ligand efficiency of the α -Me derivatives translated into cellular potencies. We therefore performed a NanoBRET assay³² for the best compound 19(*S*)-Me,



Fig. 5 The affinity boost of the (*S*)-Me is purely driven by entropy. Thermodynamic signature of bicyclic [4.3.1] aza-amides with and without α -methyl group for binding to FKBP51, as determined by ITC.




Fig. 6 (S)-Me-substituted [4.3.1] bicycles potently block FKBP12 in cells. (A) Intracellular FKBP12-NLuc engagement of compound **19**^{(S)-Me} determined by competitive NanoBRET assay. HEK293T cells stably expressing FKBP12-NLuc constructs were treated with increasing concentrations of **19**^{(S)-Me} in the presence of varying concentrations of NanoBRET tracer as shown in the upper panel. Each curve was fitted to determine an IC_{50} , which was plotted in the lower panel in dependence of the tracer concentration to determine the $K_{i^{app}}$ by Cheng-Prusoff analysis. (B) Competitive NanoBRET assay for FK506 and three bicyclic compounds. NanoBRET experiments were performed in three independent cellular assays for all samples. (C) Dose responses for FK506 and three bicyclic compounds determined in an INA-6 BRE-luc reporter assay. All cells were treated with BMP-6 (7.5 ng mL⁻¹) and indicated compounds for 18 hours. The measured luciferase activities were normalized to BMP-6 alone. Shown are the averages and standard error of the mean (SEM) of $n = 4$ biological replicates. A two-way ANOVA with Tukey's multiple comparison test and Geisser–Greenhouse correction was performed. The asterisks indicate statistical significance (* $p < 0.05$) for compound **16** vs. **19** (blue asterisks) or **19**^{(S)-Me} (red asterisks) at 1 nM and 10 nM, and compound **16** vs. FK506 (pink asterisk) at 100 nM. The other comparisons were not significant ($p > 0.05$).

which competitively bound to FKBP12 in HEK cells with an apparent $K_{i^{app}}$ of 2.9 nM (Fig. 6A). A competitive inhibition was likewise observed for compounds **18**, **18**^{(S)-Me}, **19**, and **19**^{(S)-Me} for FKBP51 (Fig. S18†), which also reflected the substantially enhanced potency of the α -methyl derivatives compared to their corresponding non-methylated analogs. For FKBP12, all tested compounds bound substantially better to intracellular FKBP12 compared to the prototypic FKBP ligand FK506 (Fig. 6B).

FKBP12 has been shown to repress BMP-signaling by binding to receptors of the ALK family and inhibition of FKBP12 has been suggested as a potential treatment option for ALK-associated diseases.^{8–10,33} To assess the potential of the α -Me [4.3.1] bicycles for these indications, we used a reporter assay based on the INA-6 myeloma cell line, INA-6 BRE-luc, that responds well to treatment with bone morphogenetic proteins (BMPs).³⁴ The BRE-luc construct employed has a BMP-responsive element derived from a mouse Id1 promoter, which is stimulated by BMP-activated SMADs.³⁵ All compounds dose-dependently potentiated BMP-6-induced SMAD signaling (Fig. 6C), with **19**, **19**^{(S)-Me} and FK506 being significantly more potent than compound **16**, consistent with the reduced biochemical affinity of the latter (Table S3†).

Conclusion

Taken together, we have identified a solvent-exposed methyl group that robustly enhances affinity by a purely entropic mechanism. Methyl groups have been repeatedly observed to profoundly boost affinity of protein ligands, *e.g.*, by filling buried hydrophobic cavities or by conformational pre-organization. Neither of these mechanisms seem to be the major driver of affinity enhancement in our case. Instead, we identified displacement of a conserved, energetically unfavorable and unusually solvent-exposed water molecule as the major origin for the enhanced affinity. Water displacement or replacement strategies have been used for ligand optimization before^{36–40} and are especially effective for buried water molecules. However, the role of exposed solvent shell water – although clearly important for binding – is still poorly understood,^{29,30,41} and the manipulation of water molecules that predominantly face the solvent have been rarely used for ligand optimization.⁴⁰ We propose that the observed water position (although energetically unfavorable) is still strongly populated because other water arrangements are even worse. It is exactly this situation that makes the displacement of this water very favorable.

Our series of C- α -Me substituted [4.3.1]-bicycles represents one of the most sophisticated model systems known to date, where affinity gain can be traced back to a purely entropically driven solvent shell reorganization with minimal other confounding factors such as conformational changes or additional ligand–protein interactions. Our findings provide a framework how solvent-exposed ligand moieties in shallow, notoriously difficult protein cavities can be used to gain binding affinity in a ligand-efficient manner. In our specific case, the introduction of a strategically positioned single methyl group improved binding affinities for all tested FKBP12 up to 10-fold, yielding the most potent FKBP12 ligands known to date, which potently enhanced BMP-signaling in a relevant cell line.

Data availability

All associated experimental and computational details are provided in the ESI†. Crystallographic data for compounds number **1**, **1**^{S-Me}, **22**, and **22**^{S-Me} have been deposited at the PDB under accession numbers 7APT (for **1**), 7APS (for **1**^{S-Me}), 7APQ (for **22**), and 7APW (for **22**^{S-Me}). Cartesian Coordinates of protein pockets and ligands and associated data obtained from the DFT calculations are available at TU repository (<https://tudatalib.ulb.tu-darmstadt.de/handle/tudatalib/2998>).

Author contributions

Jürgen M. Kolos: conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing – original draft, writing – review & editing; Sebastian Pomplun: conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing – review & editing; Sascha Jung: data curation, formal analysis, investigation, methodology, validation, visualization, writing –



original draft, writing – review & editing; Benedikt Riefl: data curation, investigation; Patrick L. Purder: data curation, investigation; Andreas M. Voll: data curation, investigation; Stephanie Merz: data curation, investigation; Monika Gnatzy: data curation, investigation; Thomas M. Geiger: data curation, investigation; Ingrid Quist-Løkken: data curation, investigation; Jerome Jatzlau: data curation, investigation; Petra Knaus: data curation, investigation; Toril Holien: funding acquisition, resources, validation; Andreas Bracher: resources, validation; Christian Meyners: formal analysis, investigation, methodology, validation, visualization; aul Czodrowski: funding acquisition, resources, validation; Vera Krewald: data curation, investigation, funding acquisition, resources, software, supervision, validation, writing – original draft, writing – review & editing; Felix Hausch: conceptualization, data curation, formal analysis, funding acquisition, project administration, resources, software, supervision, validation, visualization, writing – original draft, writing – review & editing. All authors have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Jerome Basquin, MPI of Biochemistry, Martinsried, Germany, for collecting diffraction data at SLS beamline X10SA, and the staff of ESRF and of EMBL-Grenoble for assistance and support in using beamlines ID29 and ID30B. The Lichtenberg HPC of TU Darmstadt, the Center for Scientific Computing Frankfurt and the Goethe-HLR HPC are gratefully acknowledged. This work was supported by the BMBF grants 51TaValP (16GW0290K) and iMIP (16GW0211K), the DFG grant (HA-5655-5/1) and the LOEWE cluster TRABITA.

References

- 1 E. J. Barreiro, A. E. Kümmerle and C. A. M. Fraga, *Chem. Rev.*, 2011, **111**, 5215–5246.
- 2 C. S. Leung, S. S. Leung, J. Tirado-Rives and W. L. Jorgensen, *J. Med. Chem.*, 2012, **55**, 4489–4500.
- 3 H. Schönherr and T. Cernak, *Angew. Chem., Int. Ed.*, 2013, **52**, 12256–12267.
- 4 K. Feng, R. E. Quevedo, J. T. Kohrt, M. S. Oderinde, U. Reilly and M. C. White, *Nature*, 2020, **580**, 621–627.
- 5 A. Vasilopoulos, S. W. Krska and S. S. Stahl, *Science*, 2021, **372**, 398.
- 6 M. V. Schmidt, M. Paez-Pereda, F. Holsboer and F. Hausch, *ChemMedChem*, 2012, **7**, 1351–1359.
- 7 J. M. Kolos, A. M. Voll, M. Bauder and F. Hausch, *Front. Pharmacol.*, 2018, **9**, 1425.
- 8 A. Chaikuad, I. Alfano, G. Kerr, C. E. Sanvitale, J. H. Boergermann, J. T. Triffitt, F. von Delft, S. Knapp, P. Knaus and A. N. Bullock, *J. Biol. Chem.*, 2012, **287**, 36990–36998.
- 9 B. J. Peiffer, L. Qi, A. R. Ahmadi, Y. Wang, Z. Guo, H. Peng, Z. Sun and J. O. Liu, *Cell Chem. Biol.*, 2019, **26**, 652–661.
- 10 M.-H. Larrauffie, X. Gao, X. Xia, P. J. Devine, J. Kallen, D. Liu, G. Michaud, A. Harsch, N. Savage, J. Ding, K. Tan, M. Mihalic, S. Roggo, S. M. Canham, S. M. Bushell, P. Krastel, J. Gao, A. Izaac, E. Altinoglu, P. Lustenberger, M. Salcius, F. Harbinski, E. T. Williams, L. Zeng, J. Loureiro, F. Cong, C. J. Fryer, L. Klickstein, J. A. Tallarico, R. K. Jain, D. M. Rothman and S. Wang, *Cell Chem. Biol.*, 2021, **28**, 1271–1282.
- 11 S. Gaali, A. Kirschner, S. Cuboni, J. Hartmann, C. Kozany, G. Balsevich, C. Namendorf, P. Fernandez-Vizarrá, C. Sippel, A. S. Zannas, R. Draenert, E. B. Binder, O. F. Almeida, G. Ruhter, M. Uhr, M. V. Schmidt, C. Touma, A. Bracher and F. Hausch, *Nat. Chem. Biol.*, 2015, **11**, 33–37.
- 12 P. K. A. Jagtap, S. Asami, C. Sippel, V. R. I. Kaila, F. Hausch and M. Sattler, *Angew. Chem., Int. Ed.*, 2019, **58**, 9429–9433.
- 13 A. M. Voll, C. Meyners, M. C. Taubert, T. Bajaj, T. Heymann, S. Merz, A. Charalampidou, J. Kolos, P. L. Purder, T. M. Geiger, P. Wessig, N. C. Gassen, A. Bracher and F. Hausch, *Angew. Chem., Int. Ed.*, 2021, **60**, 13257–13263.
- 14 S. Martinelli, E. A. Anderzhanova, T. Bajaj, S. Wiechmann, F. Dethloff, K. Weckmann, D. E. Heinz, T. Ebert, J. Hartmann, T. M. Geiger, M. Dong, K. Hafner, M. L. Pöhlmann, L. Jollans, A. Philipsen, S. V. Schmidt, U. Schmidt, G. Maccarrone, V. Stein, F. Hausch, C. W. Turck, M. V. Schmidt, A. Gellner, B. Kuster and N. C. Gassen, *Nat. Commun.*, 2021, **12**, 4643.
- 15 N. J. Scheuplein, N. M. Bzdyl, E. A. Kibble, T. Lohr, U. Holzgrabe and M. Sarkar-Tyson, *J. Med. Chem.*, 2020, **63**, 13355–13388.
- 16 R. J. Deshaies, *Nature*, 2020, **580**, 329–338.
- 17 Z. Guo, S. Y. Hong, J. Wang, S. Rehan, W. Liu, H. Peng, M. Das, W. Li, S. Bhat, B. Peiffer, B. R. Ullman, C.-M. Tse, Z. Tarmakova, C. Schiene-Fischer, G. Fischer, I. Coe, V. O. Paavilainen, Z. Sun and J. O. Liu, *Nat. Chem.*, 2019, **11**, 254–263.
- 18 U. K. Shigdel, S.-J. Lee, M. E. Sowa, B. R. Bowman, K. Robison, M. Zhou, K. H. Pua, D. T. Stiles, J. A. V. Blodgett, D. W. Udary, A. T. Rajczewski, A. S. Mann, S. Mostafavi, T. Hardy, S. Arya, Z. Weng, M. Stewart, K. Kenyon, J. P. Morgenstern, E. Pan, D. C. Gray, R. M. Pollock, A. M. Fry, R. D. Klausner, S. A. Townson and G. L. Verdine, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 17195.
- 19 H. A. Flaxman, C.-F. Chang, H.-Y. Wu, C. H. Nakamoto and C. M. Woo, *J. Am. Chem. Soc.*, 2019, **141**, 11759–11764.
- 20 Z. Zhang and K. M. Shokat, *Angew. Chem., Int. Ed.*, 2019, **58**, 16314–16319.
- 21 Z. Guo, Z. Cheng, J. Wang, W. Liu, H. Peng, Y. Wang, A. V. S. Rao, R. J. Li, X. Ying, P. Korangath, M. V. Liberti, Y. Li, Y. Xie, S. Y. Hong, C. Schiene-Fischer, G. Fischer, J. W. Locasale, S. Sukumar, H. Zhu and J. O. Liu, *Angew. Chem., Int. Ed.*, 2019, **58**, 17158–17162.
- 22 X. Zhang, L. M. Luukkonen, C. L. Eissler, V. M. Crowley, Y. Yamashita, M. A. Schafroth, S. Kikuchi, D. S. Weinstein,



- K. T. Symons, B. E. Nordin, J. L. Rodriguez, T. G. Wucherpfennig, L. G. Bauer, M. M. Dix, D. Stamos, T. M. Kinsella, G. M. Simon, K. A. Baltgalvis and B. F. Cravatt, *J. Am. Chem. Soc.*, 2021, **143**, 5141–5149.
- 23 Y. S. Wang, A. Kirschner, A. K. Fabian, R. Gopalakrishnan, C. Kress, B. Hoogeland, U. Koch, C. Kozany, A. Bracher and F. Hausch, *J. Med. Chem.*, 2013, **56**, 3922–3935.
- 24 M. Bischoff, C. Sippel, A. Bracher and F. Hausch, *Org. Lett.*, 2014, **16**, 5254–5257.
- 25 M. Bischoff, P. Mayer, C. Meyners and F. Hausch, *Chemistry*, 2020, **26**, 4677–4681.
- 26 S. Pomplun, Y. S. Wang, A. Kirschner, C. Kozany, A. Bracher and F. Hausch, *Angew. Chem., Int. Ed.*, 2015, **54**, 345–348.
- 27 S. Pomplun, C. Sippel, A. Hahle, D. Tay, K. Shima, A. Klages, C. M. Unal, B. Riess, H. T. Toh, G. Hansen, H. S. Yoon, A. Bracher, P. Preiser, J. Rupp, M. Steinert and F. Hausch, *J. Med. Chem.*, 2018, **61**, 3660–3673.
- 28 B. M. Dunyak and J. E. Gestwicki, *J. Med. Chem.*, 2016, **59**, 9622–9644.
- 29 F. Spyraakis, M. H. Ahmed, A. S. Bayden, P. Cozzini, A. Mozzarelli and G. E. Kellogg, *J. Med. Chem.*, 2017, **60**, 6781–6827.
- 30 S. Geschwindner and J. Ulander, *Expert Opin. Drug Discovery*, 2019, **14**, 1221–1225.
- 31 M. Bauder, C. Meyners, P. L. Purder, S. Merz, W. O. Sugiarto, A. M. Voll, T. Heymann and F. Hausch, *J. Med. Chem.*, 2021, **64**, 3320–3349.
- 32 M. T. Gnatzy, T. M. Geiger, A. Kuehn, N. Gutfreund, M. Walz, J. M. Kolos and F. Hausch, *ChemBioChem*, 2021, **22**, 2257–2261.
- 33 M. C. Taubert and F. Hausch, *Cell Chem. Biol.*, 2021, **28**, 1253–1255.
- 34 O. E. Olsen, M. Sankar, S. Elsaadi, H. Hella, G. Buene, S. R. Darvekar, K. Misund, T. Katagiri, P. Knaus and T. Holien, *J. Cell Sci.*, 2018, **131**(11), jcs220731.
- 35 O. Korchynskiy and P. ten Dijke, *J. Biol. Chem.*, 2002, **277**, 4883–4891.
- 36 P. Matricon, R. R. Suresh, Z.-G. Gao, N. Panel, K. A. Jacobson and J. Carlsson, *Chem. Sci.*, 2021, **12**, 960–968.
- 37 J. Schiebel, R. Gaspari, T. Wulsdorf, K. Ngo, C. Sohn, T. E. Schrader, A. Cavalli, A. Ostermann, A. Heine and G. Klebe, *Nat. Commun.*, 2018, **9**, 3559.
- 38 S. G. Krimmer, J. Cramer, M. Betz, V. Fridh, R. Karlsson, A. Heine and G. Klebe, *J. Med. Chem.*, 2016, **59**, 10530–10548.
- 39 E. L. Ratkova, M. Dawidowski, V. Napolitano, G. Dubin, R. Fino, M. S. Ostertag, M. Sattler, G. Popowicz and I. V. Tetko, *Chem. Commun.*, 2020, **56**, 4360–4363.
- 40 M. S. Bodnarchuk, *Drug Discovery Today*, 2016, **21**, 1139–1146.
- 41 M. Betz, T. Wulsdorf, S. G. Krimmer and G. Klebe, *J. Chem. Inf. Model.*, 2016, **56**, 223–233.

